Excellent performance of Genedrive®HCV -ID Kit in large multi-centre study
Excellent performance of Genedrive®HCV -ID Kit in large multi-centre study
Genedrive successful in PHE National Framework Agreement for Diagnostics Goods and Services
genedrive plc (LSE: GDR), the near-patient molecular diagnostics company, announces unaudited interim results for the six months to 31 December 2020.
Genedrive enters distribution agreement with Mountain Horse Solutions
New clinical guidance in the UK supports assay
Genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces the first shipments to the United States of its Genedrive® 96 SARS-CoV-2 Kits.
Distribution agreement with Beckman Coulter Life Sciences for COVID-19 PCR testing
Genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, confirms that its Genedrive 96 SARS CoV-2 Kit continues to detect all known variants of COVID-19, including the newest variants released
Genedrive notifies FDA of its intent to distribute to SARS-CoV-2 PCR test in the USA
Hepatitis C virus testing kit reveals 100% sensitivity and specificity when compared to Abbott Realtime HCV test
Turner Pope Investments (TPI) is delighted to introduce a forthcoming AIM IPO: Intuitive Investments Group plc (“IIG”). The principal behind IIG might not, however, need any introduction as David Evans
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that it will release its financial results for the year ended 30 June 2020 on Tuesday 17 November 2020.